Connect Biopharma presents Phase 2 data showing rademikibart cuts COPD treatment failures by 81%
CNTB•Connect Biopharma said rademikibart reduced treatment failures by 81% versus placebo through four weeks in a Phase 2 acute COPD trial. The company plans FDA talks in December 2026 on Phase 3 development for acute asthma, which it is prioritizing for a projected faster approval path.
1. Phase 2 trial results
In the acute COPD trial, rademikibart reduced treatment failures by 81% versus placebo through four weeks (p=0.0122) and new moderate-to-severe exacerbations by 85% (p=0.0301). Emergency department visits and hospital admissions for exacerbations fell 100% (p=0.0137). In the acute asthma trial, treatment failures fell 66% by Day 28, a result that was not statistically significant (p=0.153), while post-bronchodilator lung function improved by 130 milliliters versus placebo at Day 7 (p=0.023). Connect Biopharma plans FDA talks in December 2026 on Phase 3 acute asthma development and is prioritizing asthma for its projected faster approval path.




